- Home
- IAS vs CVAC Comparison
IAS vs CVAC Comparison
Compare IAS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- CVAC
- Stock Information
- Founded
- IAS 2009
- CVAC 2000
- Country
- IAS United States
- CVAC Germany
- Employees
- IAS N/A
- CVAC N/A
- Industry
- IAS Computer Software: Programming Data Processing
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- CVAC Health Care
- Exchange
- IAS Nasdaq
- CVAC Nasdaq
- Market Cap
- IAS 1.3B
- CVAC 1.2B
- IPO Year
- IAS 2021
- CVAC 2020
- Fundamental
- Price
- IAS $8.49
- CVAC $5.44
- Analyst Decision
- IAS Buy
- CVAC Hold
- Analyst Count
- IAS 11
- CVAC 3
- Target Price
- IAS $13.65
- CVAC $6.83
- AVG Volume (30 Days)
- IAS 711.1K
- CVAC 918.0K
- Earning Date
- IAS 08-07-2025
- CVAC 08-14-2025
- Dividend Yield
- IAS N/A
- CVAC N/A
- EPS Growth
- IAS 2607.38
- CVAC N/A
- EPS
- IAS 0.29
- CVAC 0.87
- Revenue
- IAS $549,637,000.00
- CVAC $566,039,775.00
- Revenue This Year
- IAS $13.39
- CVAC N/A
- Revenue Next Year
- IAS $11.41
- CVAC $24.04
- P/E Ratio
- IAS $29.67
- CVAC $6.27
- Revenue Growth
- IAS 13.84
- CVAC 787.60
- 52 Week Low
- IAS $6.26
- CVAC $2.37
- 52 Week High
- IAS $13.62
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- IAS 60.47
- CVAC 59.07
- Support Level
- IAS $7.83
- CVAC $5.38
- Resistance Level
- IAS $8.68
- CVAC $5.49
- Average True Range (ATR)
- IAS 0.20
- CVAC 0.06
- MACD
- IAS 0.03
- CVAC -0.06
- Stochastic Oscillator
- IAS 82.35
- CVAC 26.67
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.